Understanding the behavior of invariant NKT cells in autoimmune diseases

Journal of Neuroimmunology

Volumn 191, Issue 1-2, 2007, Pages 8-15

  Yamamura, Takashi ^a   Sakuishi, Kaori ^a   Illés, Zsolt ^b   Miyake, Sachiko ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

iNKT cells; Multiple sclerosis; NKT cells

Indexed keywords

GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL ACTIVATION; CELL FUNCTION; CROSS REACTION; DISEASE COURSE; HUMAN; IMMUNOREGULATION; INFLAMMATION; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; GALACTOSYLCERAMIDES; GLOBOSIDES; HUMANS; KILLER CELLS, NATURAL; TH1 CELLS; TH2 CELLS; TRIHEXOSYLCERAMIDES;

EID: 35848941934     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.09.014     Document Type: Review

References (69)

1. Akbari O., Stock P., Meyer E., Kronenberg M., Sidobre S., Nakayama T., Taniguchi M., Grusby M.J., DeKruyff R.H., and Umetsu D.T. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9 (2003) 582-588
2. Araki M., Kondo T., Gumperz J.E., Brenner M.B., Miyake S., and Yamamura T. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int. Immunol. 15 (2003) 279-288
3. Beaudoin L., Laloux V., Novak J., Lucas B., and Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 17 (2002) 725-736
4. Bendelac A., Savage P.B., and Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 25 (2007) 297-336
5. Bezbradica J.S., Stanic A.K., Matsuki N., Bour-Jordan H., Bluestone J.A., Thomas J.W., Unutmaz D., Van Kaer L., and Joyce S. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J. Immunol. 174 (2005) 4696-4705
6. Borg N.A., Wun K.S., Kjer-Nielsen L., Wilce M.C., Pellicci D.G., Koh R., Besra G.S., Bharadwaj M., Godfrey D.I., McCluskey J., and Rossjohn J. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448 (2007) 44-49
7. Brigl M., Bry L., Kent S.C., Gumperz J.E., and Brenner M.B. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4 (2003) 1230-1237
8. Brutkiewicz R.R. CD1d ligands: the good, the bad, and the ugly. J. Immunol. 177 (2006) 769-775
9. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., Hutchinson A., Geller M., Liu N., Annable R., Shay J., Kirchhoff K., Nishi N., Ando Y., Hayashi K., Hassoun H., Steinman R.M., and Dhodapkar M.V. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201 (2005) 1503-1517
10. Chen Y.G., Choisy-Rossi C.M., Holl T.M., Chapman H.D., Besra G.S., Porcelli S.A., Shaffer D.J., Roopenian D., Wilson S.B., and Serreze D.V. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J. Immunol. 174 (2005) 1196-1204
11. Chiba A., Kaieda S., Oki S., Yamamura T., and Miyake S. The involvement of V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis. Rheum. 52 (2005) 1941-1948
12. Coquet J.M., Kyparissoudis K., Pellicci D.G., Besra G., Berzins S.P., Smyth M.J., and Godfrey D.I. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178 (2007) 2827-2834
13. Croxford J.L., Miyake S., Huang Y.Y., Shimamura M., and Yamamura T. Invariant V(alpha)19i T cells regulate autoimmune inflammation. Nat. Immunol. 7 (2006) 987-994
14. Diao H., Kon S., Iwabuchi K., Kimura C., Morimoto J., Ito D., Segawa T., Maeda M., Hamuro J., Nakayama T., Taniguchi M., Yagita H., Van Kaer L., Onoe K., Denhardt D., Rittling S., and Uede T. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21 (2004) 539-550
15. Gillessen S., Naumov Y.N., Nieuwenhuis E.E., Exley M.A., Lee F.S., Mach N., Luster A.D., Blumberg R.S., Taniguchi M., Balk S.P., Strominger J.L., Dranoff G., and Wilson S.B. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8874-8879
16. Godfrey D.I., and Berzins S.P. NKT cells join the war on Lyme disease. Nat. Immunol. 7 (2006) 904-906
17. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., and Van Kaer L. NKT cells: what's in a name?. Nat. Rev. Immunol. 4 (2004) 231-237
18. Griseri T., Beaudoin L., Novak J., Mars L.T., Lepault F., Liblau R., and Lehuen A. Invariant NKT cells exacerbate type 1 diabetes induced by CD8 T cells. J. Immunol. 175 (2005) 2091-2101
19. Gumperz J.E., Miyake S., Yamamura T., and Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195 (2002) 625-636
20. Hur E.M., Youssef S., Haws M.E., Zhang S.Y., Sobel R.A., and Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 8 (2007) 74-83
21. Illés Z., Kondo T., Newcombe J., Oka N., Tabira T., and Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 164 (2000) 4375-4381
22. Im J.S., Tapinos N., Chae G.T., Illarionov P.A., Besra G.S., DeVries G.H., Modlin R.L., Sieling P.A., Rambukkana A., and Porcelli S.A. Expression of CD1d molecules by human schwann cells and potential interactions with immunoregulatory invariant NK T cells. J. Immunol. 177 (2006) 5226-5235
23. Jahng A., Maricic I., Aguilera C., Cardell S., Halder R.C., and Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199 (2004) 947-957
24. Jiang S., Game D.S., Davies D., Lombardi G., and Lechler R.I. Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4 +CD25 + regulatory T cells?. Eur. J. Immunol. 35 (2005) 1193-1200
25. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., and Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
26. Kent S.C., Chen Y., Clemmings S.M., Viglietta V., Kenyon N.S., Ricordi C., Hering B., and Hafler D.A. Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J. Immunol. 175 (2005) 4458-4464
27. Kim H.Y., Kim H.J., Min H.S., Kim S., Park W.S., Park S.H., and Chung D.H. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor beta1 production. J. Exp. Med. 201 (2005) 41-47
28. Kinjo Y., Tupin E., Wu D., Fujio M., Garcia-Navarro R., Benhnia M.R., Zajonc D.M., Ben-Menachem G., Ainge G.D., Painter G.F., Khurana A., Hoebe K., Behar S.M., Beutler B., Wilson I.A., Tsuji M., Sellati T.J., Wong C.H., and Kronenberg M. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7 (2006) 978-986
29. Kinjo Y., Wu D., Kim G., Xing G.W., Poles M.A., Ho D.D., Tsuji M., Kawahara K., Wong C.H., and Kronenberg M. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434 (2005) 520-525
30. Kojo S., Adachi Y., Keino H., Taniguchi M., and Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis. Rheum. 44 (2001) 1127-1138
31. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23 (2005) 877-900
32. Kronenberg M., and Gapin L. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2 (2002) 557-568
33. Lee P.T., Benlagha K., Teyton L., and Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp. Med. 195 (2002) 637-641
34. Leite-de-Moraes M.C., Lisbonne M., Arnould A., Machavoine F., Herbelin A., Dy M., and Schneider E. Ligand-activated natural killer T lymphocytes promptly produce IL-3 and GM-CSF in vivo: relevance to peripheral myeloid recruitment. Eur. J. Immunol. 32 (2002) 1897-1904
35. Levy O., Orange J.S., Hibberd P., Steinberg S., LaRussa P., Weinberg A., Wilson S.B., Shaulov A., Fleisher G., Geha R.S., Bonilla F.A., and Exley M. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J. Infect. Dis. 188 (2003) 948-953
36. Mattner J., Debord K.L., Ismail N., Goff R.D., Cantu III C., Zhou D., Saint-Mezard P., Wang V., Gao Y., Yin N., Hoebe K., Schneewind O., Walker D., Beutler B., Teyton L., Savage P.B., and Bendelac A. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 (2005) 525-529
37. McCarthy C., Shepherd D., Fleire S., Stronge V.S., Koch M., Illarionov P.A., Bossi G., Salio M., Denkberg G., Reddington F., Tarlton A., Reddy B.G., Schmidt R.R., Reiter Y., Griffiths G.M., van der Merwe P.A., Besra G.S., Jones E.Y., Batista F.D., and Cerundolo V. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J. Exp. Med. 204 (2007) 1131-1144
38. Mempel M., Ronet C., Suarez F., Gilleron M., Puzo G., Van Kaer L., Lehuen A., Kourilsky P., and Gachelin G. Natural killer T cells restricted by the monomorphic MHC class 1b CD1d1 molecules behave like inflammatory cells. J. Immunol. 168 (2002) 365-371
39. Meyer E.H., DeKruyff R.H., and Umetsu D.T. iNKT cells in allergic disease. Curr. Top. Microbiol. Immunol. 314 (2007) 269-291
40. Miyake S., and Yamamura T. Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases. Curr. Drug. Targets. Immune. Endocr. Metabol. Disord. 5 (2005) 315-322
41. Miyake S., and Yamamura T. NKT cells and autoimmune diseases: unraveling the complexity. Curr. Top. Microbiol. Immunol. 314 (2007) 251-267
42. Miyake S., and Yamamura T. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases. Int. Rev. Immunol. 26 (2007) 73-94
43. Miyamoto K., Miyake S., and Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413 (2001) 531-534
44. Nagarajan N.A., and Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J. Immunol. 178 (2007) 2706-2713
45. Naumov Y.N., Bahjat K.S., Gausling R., Abraham R., Exley M.A., Koezuka Y., Balk S.B., Strominger J.L., Clare-Salzer M., and Wilson S.B. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13838-13843
46. Novak J., Beaudoin L., Park S., Griseri T., Teyton L., Bendelac A., and Lehuen A. Prevention of type 1 diabetes by invariant NKT cells is independent of peripheral CD1d expression. J. Immunol. 178 (2007) 1332-1340
47. Ohnishi Y., Tsutsumi A., Goto D., Itoh S., Matsumoto I., Taniguchi M., and Sumida T. TCR Valpha14 natural killer T cells function as effector T cells in mice with collagen-induced arthritis. Clin. Exp. Immunol. 141 (2005) 47-53
48. Oki S., Chiba A., Yamamura T., and Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113 (2004) 1631-1640
49. Oki S., Tomi C., Yamamura T., and Miyake S. Preferential T(h)2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. Int. Immunol. 17 (2005) 1619-1629
50. Pál E., Tabira T., Kawano T., Taniguchi M., Miyake S., and Yamamura T. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells. J. Immunol. 166 (2001) 662-668
51. Porubsky S., Speak A.O., Luckow B., Cerundolo V., Platt F.M., and Grone H.J. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5977-5982
52. Rigaud S., Fondaneche M.C., Lambert N., Pasquier B., Mateo V., Soulas P., Galicier L., Le Deist F., Rieux-Laucat F., Revy P., Fischer A., de Saint Basile G., and Latour S. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444 (2006) 110-114
53. Ronet C., Darche S., Leite de Moraes M., Miyake S., Yamamura T., Louis J.A., Kasper L.H., and Buzoni-Gatel D. NKT cells are critical for the initiation of an inflammatory bowel response against Toxoplasma gondii. J. Immunol. 175 (2005) 899-908
54. Sakaguchi S., and Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int. Rev. Immunol. 24 (2005) 211-226
55. Sakuishi K., Oki S., Araki M., Porcelli S.A., Miyake S., and Yamamura T. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J. Immunol. 179 (2007) 3452-3462
56. Sharif S., Arreaza G.A., Zucker P., Mi Q.S., Sondhi J., Naidenko O.V., Kronenberg M., Koezuka Y., Delovitch T.L., Gombert J.M., Leite-De-Moraes M., Gouarin C., Zhu R., Hameg A., Nakayama T., Taniguchi M., Lepault F., Lehuen A., Bach J.F., and Herbelin A. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 7 (2001) 1057-1062
57. Spada F.M., Koezuka Y., and Porcelli S.A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188 (1998) 1529-1534
58. Speak A.O., Salio M., Neville D.C., Fontaine J., Priestman D.A., Platt N., Heare T., Butters T.D., Dwek R.A., Trottein F., Exley M.A., Cerundolo V., and Platt F.M. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5971-5976
59. Takahashi T., Nakamura K., Chiba S., Kanda Y., Tamaki K., and Hirai H. V alpha 24+ natural killer T cells are markedly decreased in atopic dermatitis patients. Hum. Immunol. 64 (2003) 586-592
60. Taniguchi M., Harada M., Kojo S., Nakayama T., and Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21 (2003) 483-513
61. Tupin E., Kinjo Y., and Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 5 (2007) 405-417
62. Ueno Y., Tanaka S., Sumii M., Miyake S., Tazuma S., Taniguchi M., Yamamura T., and Chayama K. Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of valpha14 natural killer T cells in mice. Inflamm. Bowel. Dis. 11 (2005) 35-41
63. van der Vliet H.J., Nishi N., Koezuka Y., von Blomberg B.M., van den Eertwegh A.J., Porcelli S.A., Pinedo H.M., Scheper R.J., and Giaccone G. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J. Immunol. Methods. 247 (2001) 61-72
64. van der Vliet H.J., von Blomberg B.M., Nishi N., Reijm M., Voskuyl A.E., van Bodegraven A.A., Polman C.H., Rustemeyer T., Lips P., van den Eertwegh A.J., Giaccone G., Scheper R.J., and Pinedo H.M. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100 (2001) 144-148
65. Wilson S.B., and Delovitch T.L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3 (2003) 211-222
66. Wilson S.B., Kent S.C., Patton K.T., Orban T., Jackson R.A., Exley M., Porcelli S., Schatz D.A., Atkinson M.A., Balk S.P., Strominger J.L., and Hafler D.A. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391 (1998) 177-181
67. Yanagisawa K., Seino K., Ishikawa Y., Nozue M., Todoroki T., and Fukao K. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J. Immunol. 168 (2002) 6494-6499
68. Zajonc D.M., Maricic I., Wu D., Halder R., Roy K., Wong C.H., Kumar V., and Wilson I.A. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202 (2005) 1517-1526
69. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y.P., Yamashita T., Teneberg S., Wang D., Proia R.L., Levery S.B., Savage P.B., Teyton L., and Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789